Clinical trial
PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or…
NCT00037882 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00037882 |
|---|---|
| Title | PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron |
| Official title | A Phase II Study of SCH 54031 (Peg Interferon Alpha-2B/PEG-Intron) in Subjects With Interferon-Refractory Chronic Myelogenous Leukemia |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Schering-Plough Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myeloid, Philadelphia-Positive |
| Intervention type | Drug |
| Interventions | PEG-Intron |
| Enrollment | 1 |
| Start date | Feb 1, 2001 |
| Primary completion | Dec 3, 2003 |
| Completion | Dec 3, 2003 |
| First posted | May 27, 2002 |
| Last update posted | Nov 1, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: